The intricate and resilient human heart, designed over millions of years of evolution to pump blood against the constant pull of Earth’s gravity, faces a profound physiological crisis when removed from our planet’s gravitational field. Researchers at Johns Hopkins Medicine have released the findings of a groundbreaking space biology study revealing that human bioengineered heart tissue samples sent to the International Space Station (ISS) suffered significant structural degradation, lost approximately half of their contractile strength, and developed severe rhythm disruptions during a 30-day orbital mission.
The investigation, scheduled for publication during the week of September 23 in the Proceedings of the National Academy of Sciences, provides an unprecedented cellular- and molecular-level look at how microgravity exacts a toll on cardiac muscle. By examining 48 bioengineered heart tissue samples subjected to the space environment, the scientific team has not only expanded humanity’s understanding of the cardiovascular risks astronauts face during long-duration spaceflight, but has also unlocked a novel terrestrial model for studying cardiac aging, degenerative heart disease, and prospective pharmacological interventions right here on Earth.
The Genesis of the Space Cardiac Payload
The journey of these microscopic heart tissues from terrestrial laboratories to low Earth orbit represents a triumph of modern biomedical engineering, stem cell biology, and aerospace logistics. The project was spearheaded by Deok-Ho Kim, Ph.D., a professor of biomedical engineering and medicine at the Johns Hopkins University School of Medicine.
The foundation of the experiment began years prior when Jonathan Tsui, Ph.D.—then a doctoral student in Kim’s laboratory at the University of Washington—utilized human induced pluripotent stem cells (iPSCs). By applying precise biochemical cues, Tsui coaxed these versatile stem cells to differentiate into functional cardiomyocytes, the primary muscle cells responsible for the heart’s pumping action. When Kim transitioned to the Johns Hopkins University School of Medicine in 2019, Tsui accompanied him as a postdoctoral fellow, ensuring the continuity of this ambitious space biology initiative.
To monitor the tissues in space, Tsui engineered a miniaturized, cell-phone-sized tissue chip. Within this 3D housing, the cardiac cells were suspended between two flexible micro-posts. This setup was deliberately designed to mimic the biomechanical environment and mechanical load of an adult human heart chamber, enabling the researchers to continuously measure metrics such as twitch forces (contraction strength) and beating frequency in real time.
Mission Chronology: From Lab Bench to Orbital Laboratory
The logistical hurdles of preparing living cardiac tissue for spaceflight cannot be overstated. In March 2020, as the world braced for the disruptions of the COVID-19 pandemic, Tsui traveled to Florida to hand-carry the delicate tissue chambers to the Kennedy Space Center. The payload was loaded onto a SpaceX CRS-20 commercial resupply mission bound for the ISS.
Prior to and throughout the launch sequence, Tsui meticulously maintained the tissues on the ground before they entered orbit. Once aboard the space station, the biological samples were placed into automated monitoring systems. For 30 days, the research team on Earth received telemetry data for 10 seconds every 30 minutes, tracking the precise contraction strength and irregularity patterns of the beating cells.
Astronaut responsibilities were critical to the mission’s success. NASA astronaut Jessica Meir, Ph.D., M.S., performed weekly maintenance tasks, which included refreshing the liquid nutrient media that sustained the cardiomyocytes and chemically fixing and preserving specific tissue subsets at predetermined intervals for subsequent gene expression and imaging analyses upon their return to Earth.
Simultaneously, a control group of identical cardiac tissues was maintained on Earth under identical environmental controls—housed in matching chambers and subjected to identical temperature and nutrient cycles—to serve as a baseline for comparative analysis. Following the 30-day orbital stint, the space-flown tissue chambers were returned to Earth, where Tsui and his colleagues resumed continuous data collection and maintenance.
Microgravity’s Toll: Data and Cellular Disruptions
When Devin Mair, Ph.D., a former graduate student in Kim’s laboratory and now a postdoctoral fellow at Johns Hopkins, analyzed the structural and functional data, the results painted a stark picture of cellular stress.
The heart tissues aboard the space station beat with roughly half the mechanical strength of their Earth-bound counterparts. More alarmingly, the microgravity environment triggered severe arrhythmias—irregular beating patterns that, in a whole human organ, can precipitate cardiac arrest or heart failure. Normally, healthy cardiac tissue maintains a rhythmic interval of roughly one second between contractions. For the space-flown tissues, this interval stretched to nearly five times longer than that of the terrestrial control group, though the beating interval partially normalized once the samples were returned to Earth’s gravity.
Microscopy and molecular assays revealed profound structural damage at the subcellular level:
- Sarcomere Disruption: The sarcomeres—the fundamental protein bundles responsible for muscle contraction—became significantly shorter and structurally disorganized, mimicking a classic morphological hallmark of human heart disease.
- Mitochondrial Degeneration: The mitochondria, the cellular powerhouses responsible for generating metabolic energy, underwent dramatic structural changes. They grew larger and rounder, completely losing the characteristic internal folds (cristae) essential for efficient energy production and utilization.
- Gene Expression Shift: Working alongside assistant research professor of biomedical engineering Eun Hyun Ahn, Ph.D., and Johns Hopkins doctoral student Zhipeng Dong, Mair analyzed the genetic readout of the tissues. The space-station samples exhibited a marked upregulation in genes associated with cellular inflammation and oxidative damage—pathological signatures routinely observed in clinical post-flight checkups of returning astronauts.
"Many of these markers of oxidative damage and inflammation are consistently demonstrated in post flight checks of astronauts," Mair noted, bridging the gap between in vitro tissue models and human spaceflight physiology.
Implications for Astronaut Health and Long-Duration Spaceflight
As space agencies and private aerospace companies set their sights on ambitious long-duration missions—including crewed return trips to the Moon and prospective crewed expeditions to Mars—protecting the cardiovascular health of astronauts is paramount.
Previous epidemiological and clinical studies have long established that astronauts frequently return from prolonged spaceflight exhibiting age-related cardiovascular deficits. These include diminished cardiac muscle mass, orthostatic intolerance, and persistent arrhythmias. While some of these conditions dissipate shortly after re-exposure to Earth’s gravitational field, others can become chronic, posing long-term health risks to aerospace personnel.
The Johns Hopkins study provides the cellular mechanism behind these clinical observations. By proving that microgravity directly compromises the structural integrity, energy production, and electrophysiological stability of human cardiomyocytes independent of systemic physiological feedback loops, the research gives aerospace medicine specialists a concrete target for countermeasures.
Terrestrial Applications: Combating Aging and Heart Disease on Earth
Beyond safeguarding the future of human space exploration, the Johns Hopkins platform holds immense translational value for terrestrial medicine. The physiological stress experienced by heart tissue in microgravity mimics accelerated cardiac aging and the pathology of degenerative heart disease.
Capitalizing on these insights, Kim’s research lab launched a second batch of 3D engineered heart tissues to the ISS in 2023. This subsequent mission serves as a high-throughput pharmacological screening platform to identify candidate drugs capable of shielding cardiac cells from the debilitating effects of low gravity.
Crucially, the pharmaceutical compounds being tested in orbit to protect space-bound cells against microgravity-induced degradation are the same therapeutic agents that could help aging populations on Earth maintain cardiac function and stave off age-related heart failure. Furthermore, the team is actively refining their "tissue-on-a-chip" architecture and utilizing facilities like the NASA Space Radiation Laboratory to isolate and study the distinct synergistic effects of space radiation—shielded partially while in low Earth orbit by the planet’s magnetic field—versus pure microgravity.
Institutional Support and Collaborative Frameworks
The translation of this complex interdisciplinary research from benchtop to spaceflight required robust institutional backing and financial stewardship. Funding for the multi-year initiative was provided primarily by the National Institutes of Health through grants UG3EB028094, UH3TR003519, UH3TR003271, R01HL164936, R01HL156947, and R21CA220111.
To foster commercialization and bring bioengineered tissue platforms to the broader biomedical sector, academic partnerships have also played a role. Dr. Deok-Ho Kim serves as a co-founder, scientific advisory board member, and equity holder in Curi Bio, a biotechnology firm dedicated to developing advanced tissue platforms for drug discovery and development. Additionally, Dr. Eun Hyun Ahn serves as a co-investigator or principal investigator on several supporting NIH grants.
As humanity enters a new era of commercial space habitation and interplanetary exploration, the insights gleaned from these tiny, beating strands of human heart tissue floating 250 miles above our heads will serve as a vital navigational beacon—ensuring that our cardiovascular systems can endure the vastness of space while simultaneously offering new healing pathways for millions of patients back home on Earth.
